Nick Visser is a senior reporter on HuffPost’s breaking news team, covering the environment, U.S. politics and world news. Originally based in New York, he now lives in Sydney.
Pfizer told pharmacies and clinics this week it will soon price a five-day course of COVID-19 treatment Paxlovid at almost $1,400, more than two-and-a-half times what the federal government has paid for the antiviral pills.Wednesday that Pfizer plans to price a course of the oral antiviral at $1,390, far higher than the U.S. had paid at $529. The drug was authorized in the U.S. in 2021 and quickly became a key tool to help treat those at risk of developing severe infections from COVID-19.
“Pricing for Paxlovid is based on the value it provides to patients, providers and health care systems due to its important role in helping reduce COVID-19-related hospitalizations and deaths,” a spokesperson for Pfizer told the Journal, adding that many people will pay “as little as $0” under the copay assistance program through 2028.for adults who test positive for COVID-19 and are treated with Paxlovid.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Norwich Township firefighter arrested on child sexual abuse material chargePolice said one person was detained in connection with the incident.
Read more »
One charge dropped against Houston Rockets player accused of beating, choking girlfriend at New York hotelKevin Porter, Jr. was charged with assault and strangulation after New York police said he hit his girlfriend multiple times and put his hands around her neck.
Read more »
Pfizer and Moderna's updated COVID shots fully approved for people 12 and olderThe Pennsylvania Breast Cancer Coalition is celebrating 30 years.
Read more »
Rams cornerback Derion Kendrick arrested on gun charge after Hollywood traffic stopLos Angeles Rams starting cornerback Derion Kendrick was arrested early Monday morning on a felony charge of carrying a concealed weapon.
Read more »